Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Accured Expenses: 2019-2024

Historic Change in Accured Expenses for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $3.0 million.

  • Keros Therapeutics' Change in Accured Expenses fell 155.08% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.0 million, marking a year-over-year decrease of 169.74%. This contributed to the annual value of $3.0 million for FY2024, which is 43.85% down from last year.
  • As of FY2024, Keros Therapeutics' Change in Accured Expenses stood at $3.0 million, which was down 43.85% from $5.3 million recorded in FY2023.
  • Keros Therapeutics' Change in Accured Expenses' 5-year high stood at $5.3 million during FY2022, with a 5-year trough of $2.6 million in FY2020.
  • Over the past 3 years, Keros Therapeutics' median Change in Accured Expenses value was $5.3 million (recorded in 2023), while the average stood at $4.5 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 117.46% in 2020, then crashed by 43.85% in 2024.
  • Over the past 5 years, Keros Therapeutics' Change in Accured Expenses (Yearly) stood at $2.6 million in 2020, then increased by 2.39% to $2.7 million in 2021, then soared by 100.68% to $5.3 million in 2022, then dropped by 1.22% to $5.3 million in 2023, then crashed by 43.85% to $3.0 million in 2024.